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Abstract: Krzyzosiak et al, describe a paradigm changing scheme to identify 
inhibitors targeting regulatory subunits of serine/threonine PP1 phosphatases 
complexes. They characterize a selective R15B phosphatase regulatory 
subunit inhibitor termed Raphin1. This protects cells from stress, delaying 
neurodegeneration in a mouse model of Huntington’s disease, illustrating the 
potential of this approach. 
 
The ability of a cell to rapidly slow down protein synthesis following exposure 
to a stress is one of the fundamental responses that enables eukaryotic cells 
to tolerate such conditions. This increases capacity of chaperones and 
proteosomal machinery to clear misfolded proteins before they accumulate to 
dangerous levels (Donnelly et al., 2013)). Key to the ability of stress to 
attenuate protein synthesis, is the phosphorylation of the a-subunit of the 
eukaryotic translation initiation factor 2 (eIF2a) on Serine 51. There are four 
Ser51 eIF2α kinases (general control non-depressible (GCN2), heme-
regulated inhibitor (HRI), PKR-like endoplasmic reticulum kinase (PERK) and 
protein kinase R (PKR)) that all phosphorylate Ser51 of eIF2a in response to 
different types of stress, illustrating the importance of this response pathway 
(Donnelly et al., 2013) (Figure 1 A).  
 
Screens undertaken some years ago identified two compounds termed 
Guanabenz (Tsaytler et al., 2011) and Sephin1 (Das et al., 2015) that 
protected cells from otherwise lethal doses of endoplasmic reticulum stress 
that induces unfolding of proteins. These compounds inhibit a protein 
phosphatase 1 (PP1) holoenzyme (complex consisting of the PP1 catalytic 
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subunit and a regulatory subunit termed R15A) that acts to dephosphorylate 
eIF2a at Ser51 (Harding et al., 2009) and thus they exert their stress 
protective properties by prolonging the beneficial effects of eIF2α 
phosphorylation.  
 
Cells possess another PP1 regulatory subunit termed R15B, which is 28% 
identical to R15A, that appears to play a more general role in 
dephosphorylating eIF2a (Tsaytler et al., 2011 and Das, 2015 #13) (Figure 
1A). Guanabenz and Sephin-1 are selective for the R15A PP1 complex and 
do not significantly inhibit R15B PP1. Krzyzosiak et al reasoned that targeting 
the R15B:PP1 complex instead of R15A could be a better choice to obtain 
inhibitors that were effective against diverse stress. This was an ambitious 
quest, as PP1 holoenzyme complexes had never been targeted previously.  
 
To achieve this, Krzyzosiak and co-workers reconstituted the partial 
R15A/PP1 and R15B-PP1 holoenzymes on a surface plasmon resonance 
sensor chip and undertook a compound binding screen with a small library of 
69 derivatives of Ganabenz. This lead to the discovery of the compound 
termed Raphin1, that bound R15B-PP1 with 30-fold selectivity over the 
R15A-PP1 complex. When used in cells, Raphin1 increased eIF2a 
phosphorylation and decreased protein synthesis. These effects were lost 
following knock-out of the R15B subunit, confirming that the mechanism of 
action of Raphin1 was indeed mediated through R15B. The effects on 
Raphin1 on eIF2a phosphorylation and protein synthesis were transient, with 
recovery observed after around 10 hours. Further analysis revealed that this 
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was caused by marked upregulation of the R15A subunit occurring after 
about 2 h of Raphin1 administration. More work is needed to establish the 
mechanism by which cells upregulate R15A following inhibition of R15B.  
 
Raphin1, when administered to mice at doses as low as 2mg/kg, 
accumulated in tissues including brain at sufficiently high concentrations to 
inhibit R15B and had no reported adverse effects on the animals. When 
Raphin1 was administered once per day to a mouse model of Huntington’s 
disease over a 6-week period, it markedly decreased insoluble Huntingtin 
protein aggregates and also significantly delayed disease onset.  There are 
currently no treatments that prevent or even delay disease progression of 
Huntington’s and other neurodegenerative disorders caused by abnormal 
protein misfolding. In future work it will be vital to further explore whether 
Raphin1 or other R15B inhibitors have therapeutic benefit for these 
devastating diseases in humans. 
 
Research into the regulation of protein phosphorylation over the last decades 
has focused on kinases and the examination of phosphatases has stagnated. 
Kinase inhibitors have become one of the pharmaceutical companies favored 
targets, with at least 48 clinically approved compounds (http://www.kinase-
screen.mrc.ac.uk/phosphorylation-ubiquitylation-drug-discovery) and many 
more are in clinical development (Ferguson and Gray, 2018). The only drugs 
that target a protein phosphatase complex are the macrolide FK506 and its 
derivatives, immunosuppressive agents developed over 20 years ago. These 
bind to the immunophilin FKBP12, and suppress activity the calcineurin 
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(protein phosphatase 3) complex, thereby blocking activation of the 
transcription factor NFATc (nuclear factor of activated T cell cytoplasmic) in T 
cells (Rusnak and Mertz, 2000). To our knowledge only a single phosphatase 
inhibitor termed LB100, that targets PP2A, is currently in early phase clinical 
trials, for treatment of recurrent glioblastoma. Selective allosteric inhibitors of 
a variety of tyrosine phosphatases including PTP1B (Protein tyrosine 
phosphatase 1B-obesity and associated co-morbidities), SHP2 (the tyrosine 
phosphatase produced by the oncogene PTPN11-oncology) and SHP1 
(produced by the PTPN6 gene oncology and immune disorders) have been 
elaborated, but research is still at the preclinical stage (He et al., 2014). 
 
Drug discovery efforts targeting the catalytic subunits of PP1 were quickly 
abandoned in the 1990’s as natural compounds including microcystin and 
calyculin A, that inhibited all PP1 holoenzymes were found to be highly toxic 
(Cohen, 2002). It was assumed infeasible to target specific PP1 
holoenzymes. The work performed by Krzyzosiak et al, provides much-
needed ammunition that crafting selective inhibitors targeting PP1 
holoenzymes is indeed achievable. Raphin-1 binding to R15B induces a 
conformational change resulting in it becoming targeted for p97 and 
proteasome mediated degradation in vivo (KRZYZOSIAK Ref). However, 
there are other mechanisms of action that could be considered for developing 
inhibitors of PP1 holoenzymes in future studies, increasing opportunity for 
success (Figure 1 B). These include blocking the PP1 regulatory subunit from 
accessing its physiological substrate or inducing disassembly of regulatory 
and catalytic subunits. There may also be other functionally critical pockets 
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on certain PP1 holoenzymes that could be exploited (Fig 1B). In future work, 
we would advocate incorporating unbiased quantitative total and 
phosphoproteomic into the workflow (that was not utilized in the Krzyzosiak et 
al study), to better characterize the in vivo specificity of identified PP1 
holoenzyme inhibitors.  
 
The Krzyzosiak study represents a major step forward, providing the 
strongest evidence to date that PP1 holoenzymes are indeed druggable. The 
research validates R15B as a promising target to slow progression of a range 
of devastating neurodegenerative conditions. Perhaps the greatest challenge 
going forward will be to define which PP1 holoenzyme complexes should be 
targeted to treat specific diseases	 (Ferreira et al., 2018) as the physiological 
roles of the vast majority of these enzymes, of which there is over 200, is 
unknown. Fundamental mechanistic research in this neglected field of 
phosphatase biology is urgently needed. Defining the key set of physiological 
substrates that individual PP1 holoenzymes act upon, would significantly 
contribute to the growing armory of approaches that can be deployed to 
modulate protein phosphorylation for treatment of disease. 
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Figure legend 
 
 
Protein phosphatase holocomplexes are possible drug targets. 
A) Eukaryotic translation initiation factor 2 (eIF2a) is phosphorylated at Ser51 
during stress response to slow down translation. Four different kinases 
(PERK, PKR, CGN2 and HRI) can phosphorylate eIF2a depending on type of 
stress. Two different but related protein phosphatase 1 (PP1) holoenzymes 
(complex consisting of the PP1 catalytic subunit (PP1c) and a regulatory 
subunit termed R15A or R15B) counteract these phosphorylations. 
The newly discovered drug Raphin1 binds selectively to the regulatory subunit 
R15B, causing a conformational change to the protein structure that ultimately 
leads to degradation of the subunit, thus inactivating the phosphatase 
complex. 
B) Alternative strategies could be used to target the PP1 holoenzymes (PP1c 
+ R). Inhibitors (I) can be designed: 1) to block the binding of the regulatory 
subunit (R) with the substrate (S) (substrate recognition pocket); 2) to block 
the binding between PP1c and the regulatory subunit (PP1 binding pocket); 3) 
to interfere with other essential domains of the regulatory subunit (other 
functional pocket). 
 
  
	 8	
 
References 
 
Cohen, P.T. (2002). Protein phosphatase 1--targeted in many directions. J 
Cell Sci 115, 241-256. 
Das, I., Krzyzosiak, A., Schneider, K., Wrabetz, L., D'Antonio, M., Barry, N., 
Sigurdardottir, A., and Bertolotti, A. (2015). Preventing proteostasis 
diseases by selective inhibition of a phosphatase regulatory subunit. 
Science 348, 239-242. 
Donnelly, N., Gorman, A.M., Gupta, S., and Samali, A. (2013). The eIF2alpha 
kinases: their structures and functions. Cell Mol Life Sci 70, 3493-3511. 
Ferguson, F.M., and Gray, N.S. (2018). Kinase inhibitors: the road ahead. Nat 
Rev Drug Discov 17, 353-377. 
Ferreira, M., Beullens, M., Bollen, M., and Van Eynde, A. (2018). Functions 
and therapeutic potential of protein phosphatase 1: Insights from mouse 
genetics. Biochim Biophys Acta. 
Harding, H.P., Zhang, Y., Scheuner, D., Chen, J.J., Kaufman, R.J., and Ron, 
D. (2009). Ppp1r15 gene knockout reveals an essential role for translation 
initiation factor 2 alpha (eIF2alpha) dephosphorylation in mammalian 
development. Proc Natl Acad Sci U S A 106, 1832-1837. 
He, R.J., Yu, Z.H., Zhang, R.Y., and Zhang, Z.Y. (2014). Protein tyrosine 
phosphatases as potential therapeutic targets. Acta Pharmacol Sin 35, 
1227-1246. 
Rusnak, F., and Mertz, P. (2000). Calcineurin: form and function. Physiol Rev 
80, 1483-1521. 
Tsaytler, P., Harding, H.P., Ron, D., and Bertolotti, A. (2011). Selective 
inhibition of a regulatory subunit of protein phosphatase 1 restores 
proteostasis. Science 332, 91-94. 
 
R1
5B
PP1c
R1
5A
PP1c
P eIF2 eIF2
TRANSLATION TRANSLATION
Constitutive Stress induced
PERK
PKR HRI
CGN2
R1
5B
PP1c
Raphin1
R
15
B
PP1c
R
15
B
PP1c
Proteasome 
Degradation
A
B
R
PP1c
S
I
Other functional
pocket
3
1
2
substrate 
binding
PP1 
binding
α α
